GC4711 and GC4419 constitute two potential candidate SOD mimetics developed to reduce radiation‐induced severe oral mucositis in cancer patients, whose safety and tolerability are currently being tested in phase I clinical trials in two separate healthy cohorts (NCT03099824, NCT03762031). Here, SOD1 is linked to cancer.